Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women.

ABSTRACT:

Importance

Clinical trials have demonstrated the antifracture efficacy of bisphosphonate drugs for the first 3 to 5 years of therapy. However, the efficacy of continuing bisphosphonate for as long as 10 years is uncertain.

Objective

To examine the association of discontinuing bisphosphonate at study entry, discontinuing at 2 years, and continuing for 5 additional years with the risk of hip fracture among women who had completed 5 years of bisphosphonate treatment at study entry.

Design, setting, and participants

This cohort study included women who were members of Kaiser Permanente Northern and Southern California, 2 integrated health care delivery systems, and who had initiated oral bisphosphonate and completed 5 years of treatment by January 1, 2002, to September 30

SUBMITTER: Izano MA 

PROVIDER: S-EPMC8436954 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature